Regnum Corp (RGMP)

Overview

Regnum Corp. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics aimed at treating rare and infectious diseases. At the heart of Regnum Corp.'s pipeline is Leronlimab (PRO 140), a therapeutic innovation designed to combat human immunodeficiency virus (HIV) by preventing its entry into human cells. As an antagonist of the C—C chemokine receptor type 5 (CCR5), Leronlimab represents a targeted approach to HIV treatment, aiming to offer a new hope for patients living with this challenging condition. Situated in the vibrant city of New York, Regnum Corp. operates under the guidance of its parent company, Phoenixus AG. This strategic partnership underscores the company's commitment to groundbreaking medical research and the development of life-saving treatments.

Products and Services

• Leronlimab (PRO 140)

Leronlimab (PRO 140) is the flagship product of Regnum Corp., symbolizing the company's innovative thrust into the realm of infectious disease treatment. This monoclonal antibody is engineered as a C—C chemokine receptor type 5 antagonist, thereby inhibiting the HIV virus's ability to enter and infect human cells. The development of Leronlimab represents a significant advancement in HIV treatment strategies, offering a potentially more targeted and effective therapy option for patients battling this virus. Regnum Corp.'s commitment to advancing Leronlimab through clinical trials and towards commercialization is a testament to their focus on addressing unmet medical needs within the infectious disease landscape.